Dermata Stock Buy Hold or Sell Recommendation

DRMA -  USA Stock  

USD 1.68  0.17  11.26%

Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Dermata Therapeutics is 'Strong Buy'. Macroaxis provides Dermata Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DRMA positions. The advice algorithm takes into account all of Dermata Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.

Dermata Advice 

 
Refresh
The advice is provided from Dermata Therapeutics' buy-and-hold perspective. Continue to Dermata Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Dermata and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Dermata Therapeutics.

Execute Dermata Therapeutics Buy or Sell Advice

The Dermata recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Dermata Therapeutics. Macroaxis does not own or have any residual interests in Dermata Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Dermata Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Dermata TherapeuticsBuy Dermata Therapeutics
Strong Buy

Volatility

Very riskyDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Above AverageDetails

Economic Sensitivity

Hyperactively responds to market trendsDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Dermata Therapeutics has a Risk Adjusted Performance of (0.12), Jensen Alpha of (1.35), Total Risk Alpha of (1.46) and Treynor Ratio of (0.60)
We provide trade advice to complement the prevailing expert consensus on Dermata Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. Use Dermata Therapeutics cash per share, as well as the relationship between the cash flow from operations and number of employees to ensure your buy or sell decision on Dermata Therapeutics is adequate. Please also check Dermata Therapeutics cash and equivalents to verify your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Dermata Therapeutics Trading Alerts and Improvement Suggestions

Dermata Therapeutics generated a negative expected return over the last 90 days
Dermata Therapeutics has high historical volatility and very poor performance
Dermata Therapeutics may become a speculative penny stock
Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years
Dermata Therapeutics was previously known as Dermata Therapeutics and was traded on NASDAQ Exchange under the symbol DRMAW.
Net Loss for the year was (8.31 M).
Dermata Therapeutics currently holds about 12.6 M in cash with (4.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51.
Dermata Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 46.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Bradrick Brittany of 10000 shares of Dermata Therapeutics subject to Rule 16b-3

Dermata Therapeutics current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dermata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dermata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price11.50
Target Median Price11.50
Target High Price14.00
Recommendation Mean2.00
Number Of Analyst Opinions2
Target Low Price9.00
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Dermata Therapeutics Returns Distribution Density

The distribution of Dermata Therapeutics' historical returns is an attempt to chart the future uncertainty of Dermata Therapeutics' future price movements. The chart of the probability distribution of Dermata Therapeutics stock daily returns describes the distribution of returns around its average expected value. We use Dermata Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Dermata Therapeutics returns is essential to provide solid investment advice for Dermata Therapeutics stock.
Mean Return-1.32Value At Risk-12.26
Potential Upside13.86Standard Deviation8.41
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Dermata Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Dermata Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Dermata Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Dermata Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Dermata stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
-1.35
β
Beta against DOW2.21
σ
Overall volatility
8.80
Ir
Information ratio -0.16

Dermata Therapeutics Volatility Alert

Dermata Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Dermata Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Dermata Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Dermata Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Dermata Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Dermata Therapeutics Implied Volatility

Dermata Therapeutics' implied volatility exposes the market's sentiment of Dermata Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Dermata Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Dermata Therapeutics stock will not fluctuate a lot when Dermata Therapeutics' options are near their expiration.

Dermata Therapeutics Fundamentals Vs Peers

Comparing Dermata Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Dermata Therapeutics' direct or indirect competition across all of the common fundamentals between Dermata Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Dermata Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Dermata Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Dermata Therapeutics to competition
FundamentalsDermata TherapeuticsPeer Average
Current Valuation306.03 K16.62 B
Shares Outstanding8.33 M571.82 M
Shares Owned by Insiders46.17 %10.09 %
Shares Owned by Institutions2.71 %39.21 %
Number of Shares Shorted50.12 K4.71 M
Price to Book1.01 X9.51 X
EBITDA(5.8 M)3.9 B
Net Income(8.31 M)570.98 M
Cash and Equivalents12.6 M2.7 B
Cash per Share1.51 X5.01 X
Current Ratio11.45 X2.16 X
Book Value Per Share1.50 X1.93 K
Cash Flow from Operations(4.43 M)971.22 M
Short Ratio0.34 X4.00 X
Earnings Per Share(3.09) X3.12 X
Number of Employees718.84 K
Market Capitalization12.58 M19.03 B
   Acquisition by Bradrick Brittany of 10000 shares of Dermata Therapeutics subject to Rule 16b-3 [view details]

Dermata Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Dermata . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution39044.92
Daily Balance Of Power0.68
Rate Of Daily Change1.11
Day Median Price1.65
Day Typical Price1.66
Market Facilitation Index0.0
Price Action Indicator0.12

About Dermata Therapeutics Buy or Sell Advice

When is the right time to buy or sell Dermata Therapeutics? Buying financial instruments such as Dermata Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Dermata Therapeutics investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2010 2020 2021 2022 (projected)
Current Assets2.07 M605.45 K544.91 K849.1 K
Total Assets2.07 M605.45 K544.91 K849.16 K

Use Investing Ideas to Build Portfolios

In addition to having Dermata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Robots And Drones Thematic Idea Now

Robots And Drones
Robots And Drones Theme
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. Robots And Drones theme has 42 constituents.
View All  Next Launch Robots And Drones
Continue to Dermata Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Dermata Therapeutics information on this page should be used as a complementary analysis to other Dermata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Dermata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.